Drug Profile
Research programme: paclitaxel nanoparticles - Allist Pharmaceuticals
Alternative Names: Nanopaclitaxel; Nanoparticulate paclitaxelLatest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator Allist Pharmaceuticals
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in China (IV, Infusion)